Effectiveness of Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion for Children with Type 1 Diabetes Mellitus in Clinical Practice
Table 2
Glycosylated hemoglobin (HbA1c) levels, poor glycemic control rates, insulin dosages, BMI, and frequency of blood glucose monitoring in the experimental (1A, 2A) and control (1B, 2B) groups.
T0
T1
T2
T3
T4/T5
HbA1c level (%)
Group 1A
8.03 ± 1.41
7.35 ± 1.24△
7.37 ± 1.00△
7.61 ± 1.22
7.61 ± 1.15
Group 1B
8.01 ± 1.92
7.89 ± 2.05
8.21 ± 2.05
8.41 ± 2.04
8.72 ± 1.81△
0.40
0.10
<0.01
<0.01
<0.01
Group 2A
8.39 ± 1.23
8.49 ± 1.40
8.36 ± 1.25
9.03 ± 1.59
9.24 ± 1.43
Group 2B
8.67 ± 1.44
9.04 ± 1.96
9.19 ± 1.79△
8.96 ± 1.94
9.28 ± 1.75△
0.87
0.48
0.04
0.92
0.40
Poor glycemic control rate (%)
Group 1A
18
11.5
4.9
13.2
15.4
Group 1B
22.1
24
32.8
28.6
32.7
0.52
0.04
<0.01
0.03
0.04
Group 2A
30.4
26.1
21.7
47.8
45
Group 2B
45.7
43.5
50
37.8
54.1
0.23
0.16
0.02
0.43
0.51
Insulin dosage (U/kg/d)
Group 1A
0.59 ± 0.36
0.54 ± 0.29
0.58 ± 0.26
0.68 ± 0.17
0.76 ± 0.19△
Group 1B
0.39 ± 0.24
0.41 ± 0.23
0.47 ± 0.22△
0.57 ± 0.23△
0.70 ± 0.25△
<0.01
<0.01
<0.01
<0.01
<0.01
Group 2A
0.58 ± 0.27
0.72 ± 0.27
0.79 ± 0.25△
0.82 ± 0.28△
0.84 ± 0.16△
Group 2B
0.66 ± 0.23
0.69 ± 0.23
0.71 ± 0.21△
0.74 ± 0.20△
0.83 ± 0.24△
0.19
0.42
0.24
0.16
0.67
BMI (kg/m2)
Group 1A
16.74 ± 2.26
17.17 ± 2.00△
17.25 ± 2.01
17.61 ± 1.22△
17.61 ± 1.15
Group 1B
16.57 ± 1.92
16.57 ± 2.08
16.60 ± 2.07
16.96 ± 2.07△
17.21 ± 2.49△
0.61
0.02
0.02
0.03
0.53
Group 2A
17.54 ± 1.97
18.13 ± 1.99△
18.70 ± 2.67△
18.75 ± 2.34△
19.50 ± 3.08△
Group 2B
17.12 ± 2.45
17.39 ± 2.54
17.73 ± 2.41
17.73 ± 2.57
17.62 ± 2.59△
0.48
0.07
<0.01
0.03
0.05
Blood glucose monitoring ≥4 times/day (%)
Group 1A
76.30
71.80
63.40
43.20
40.00
Group 1B
62.00
54.00
51.00
38.50
47.90
0.05
0.09
0.24
0.65
0.49
Group 2A
70.00
66.70
42.90
33.30
28.60
Group 2B
31.30
31.30
30.80
21.40
8.30
0.13
0.06
0.52
0.47
0.18
*Group 1A versus group 1B; †group 2A versus group 2B; versus baseline.
